A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Risankizumab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 18 Sep 2019 Planned End Date changed from 29 Nov 2019 to 20 Feb 2020.
- 18 Sep 2019 Planned primary completion date changed from 29 Nov 2019 to 20 Feb 2020.
- 13 Mar 2019 Planned End Date changed from 25 Jun 2020 to 29 Nov 2019.